Untersuchung gezielter Therapien zur Behandlung erwachsener Teilnehmer mit aktiver psoriatischer Arthritis
Eine multizentrierte, randomisierte Plattformstudie mit gezielten Therapien zur Behandlung erwachsener Probanden mit aktiver psoriatischer Arthritis
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-Mail: abbvieclinicaltrials@abbvie.com
Studienorte
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankreich, 06001
- Rekrutierung
- Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
-
-
Auvergne-Rhône-Alpes
-
Caluire-et-Cuire, Auvergne-Rhône-Alpes, Frankreich, 69300
- Rekrutierung
- Infirmerie Protestante De Lyon /ID# 273731
-
-
Indre-et-Loire
-
Chambray-lès-Tours, Indre-et-Loire, Frankreich, 37170
- Rekrutierung
- Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
-
-
Loiret
-
Orléans, Loiret, Frankreich, 45067
- Abgeschlossen
- Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankreich, 33076
- Abgeschlossen
- Chu Bordeaux - Hopital Pellegrin /ID# 273390
-
-
-
-
Quebec
-
Sherbrooke, Quebec, Kanada, J1G 2E8
- Rekrutierung
- Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
-
Trois-Rivières, Quebec, Kanada, G9A 3X2
- Rekrutierung
- Centre de Recherche Musculo-Squelettique /ID# 274397
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7H 0P4
- Rekrutierung
- Dr. Latha Naik Medical Professional Corporation /ID# 272803
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-068
- Rekrutierung
- Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
-
-
Masovian Voivodeship
-
Pruszków, Masovian Voivodeship, Polen, 05-800
- Rekrutierung
- MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
-
Warsaw, Masovian Voivodeship, Polen, 02-665
- Rekrutierung
- Centrum Medyczne Reuma Park /ID# 273301
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-351
- Abgeschlossen
- Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
-
-
Warmian-Masurian Voivodeship
-
Elblag, Warmian-Masurian Voivodeship, Polen, 82-300
- Abgeschlossen
- Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
-
-
-
-
-
Uherské Hradiště, Tschechien, 686 01
- Rekrutierung
- Medical Plus Research /ID# 272363
-
Zlín, Tschechien, 760 01
- Rekrutierung
- PV Medical Services /ID# 272368
-
-
Brno-mesto
-
Brno, Brno-mesto, Tschechien, 638 00
- Rekrutierung
- Revmatologie /ID# 272367
-
-
Moravian-Silesian Region
-
Hlučín, Moravian-Silesian Region, Tschechien, 748 01
- Rekrutierung
- L.K.N. Arthrocentrum /ID# 272366
-
-
-
-
-
Budapest, Ungarn, 1027
- Rekrutierung
- Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
-
Budapest, Ungarn, 1023
- Rekrutierung
- Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
-
-
Borsod-Abauj Zemplen county
-
Miskolc, Borsod-Abauj Zemplen county, Ungarn, 3529
- Rekrutierung
- Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
-
-
Fejér
-
Székesfehérvár, Fejér, Ungarn, 8000
- Rekrutierung
- Complex Rendelo Med Zrt. /ID# 272570
-
Veszprém, Fejér, Ungarn, 8200
- Rekrutierung
- Vital-Medicina /ID# 272855
-
-
-
-
California
-
Huntington Beach, California, Vereinigte Staaten, 92648-5994
- Rekrutierung
- Newport Huntington Medical Group /ID# 272764
-
Kontakt:
- Site Coordinator
- Telefonnummer: 714-923-7112
-
-
Florida
-
Avon Park, Florida, Vereinigte Staaten, 33825
- Rekrutierung
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
-
Kontakt:
- Site Coordinator
- Telefonnummer: 863-314-8555
-
Clearwater, Florida, Vereinigte Staaten, 33765
- Rekrutierung
- Clinical Research Of West Florida - Phase I Unit /ID# 273198
-
Orlando, Florida, Vereinigte Staaten, 32819
- Rekrutierung
- HMD Research LLC /ID# 273086
-
Tamarac, Florida, Vereinigte Staaten, 33321
- Rekrutierung
- West Broward Rheumatology Associates /ID# 272892
-
Tampa, Florida, Vereinigte Staaten, 33606
- Rekrutierung
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
-
Kontakt:
- Site Coordinator
- Telefonnummer: (813) 870-1292
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
-
Skokie, Illinois, Vereinigte Staaten, 60076
- Abgeschlossen
- Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
-
Willowbrook, Illinois, Vereinigte Staaten, 60527
- Rekrutierung
- Willow Rheumatology and Wellness /ID# 277354
-
-
Maryland
-
Cumberland, Maryland, Vereinigte Staaten, 21502
- Abgeschlossen
- Klein & Associates /ID# 272829
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Rekrutierung
- Dartmouth-Hitchcock Medical Center /ID# 272702
-
Kontakt:
- Site Coordinator
- Telefonnummer: 603-650-4717
-
-
Ohio
-
Middleburg Heights, Ohio, Vereinigte Staaten, 44130
- Rekrutierung
- Paramount Medical Research and Consulting /ID# 272757
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Vereinigte Staaten, 16635
- Rekrutierung
- Altoona Center For Clinical Research /ID# 272593
-
Kontakt:
- Site Coordinator
- Telefonnummer: 814-296-6108
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 38119
- Rekrutierung
- Private Practice - Dr. Ramesh C. Gupta /ID# 272897
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78745
- Rekrutierung
- Tekton Research - West Gate /ID# 272765
-
Frisco, Texas, Vereinigte Staaten, 75035
- Rekrutierung
- Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
-
Houston, Texas, Vereinigte Staaten, 77089-6142
- Rekrutierung
- Accurate Clinical Research - Houston /ID# 272754
-
San Antonio, Texas, Vereinigte Staaten, 78251
- Rekrutierung
- Tekton Research, LLC /ID# 272901
-
Tomball, Texas, Vereinigte Staaten, 77375
- Rekrutierung
- DM Clinical Research - Tomball /ID# 272760
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
- Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
- Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
- Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
- Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA
Exclusion Criteria:
- Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
- Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
- Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
- History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Substudy 1: Risankizumab Monotherapy
Participants will receive risankizumab |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 1: Lutikizumab Monotherapy
Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 1: Lutikizumab and Risankizumab Combination Therapy
Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
Experimental: Substudy 2: ABBV-701 Monotherapy
Participants will initially receive ABBV-701. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 2: Risankizumab Monotherapy
Participants will receive risankizumab. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 2: ABBV-701 and Risankizumab Combination Therapy
Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
Experimental: Substudy 3: ABBV-547 Dose A
Participants will receive ABBV-547 Dose A. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 3: ABBV-547 Dose B
Participants will receive ABBV-547 Dose B. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 3: ABBV-547 Dose C
Participants will receive ABBV-547 Dose C. |
Subcutaneous (SC) Injection |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Zeitfenster: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:
|
At Week 16
|
|
Number of Participants With Adverse Events (AEs)
Zeitfenster: Up to Week 52
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Week 52
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
Zeitfenster: At Week 16
|
A participant was classified as achieving MDA if 5 of the following 7 criteria were met:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Zeitfenster: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Zeitfenster: At Week 16
|
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
|
At Week 16
|
|
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
Zeitfenster: At Week 16
|
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%. |
At Week 16
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: ABBVIE INC., AbbVie
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Knochenerkrankungen
- Erkrankungen des Bewegungsapparates
- Arthritis
- Gelenkerkrankungen
- Erkrankungen der Wirbelsäule
- Spondylarthropathien
- Hautkrankheiten, papulosquamös
- Hautkrankheiten
- Spondylarthritis
- Spondylitis
- Schuppenflechte
- Haut- und Bindegewebserkrankungen
- Arthritis, Psoriasis
- risankizumab
- Lutikizumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- M25-191
- 2024-519291-11 (Substudy 1) (Andere Kennung: EU CT)
- 2026-525937-21 (Substudy 2) (Andere Kennung: EU CT)
- 2026-527719-41 (Substudy 3) (Andere Kennung: EU CT)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-Sharing-Zeitrahmen
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-Sharing-Zugriffskriterien
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .